AstraZeneca Sees Growth Opportunities in Japan As Population Continues To Age
This article was originally published in PharmAsia News
AstraZeneca KK’s young president Gabriel Baertschi is eying more partnerships for cardiovascular, oncology and respiratory therapies in Japan.
You may also be interested in...
Japan may try to accelerate the increased usage of generic drugs by drastically reducing prices, part of an effort to slash skyrocketing health care costs at a time when the country’s public debt is reaching a record high.
Kyowa Hakko Kirin is committed to expansion, and the deal with Ultragenyx for a first-in-class therapy of a rare bone disorder is small but establishes a clinical trial foothold overseas